Feb 23, 2017
In the case of MGC Pharmaceuticals (ASX: MXC), this ASX-dwelling green thumb is making a bee-line for the global medical cannabis market. This most recent move by the Australian government opens up several commercial channels for MXC with regard to its medical cannabis and cosmetics plays, given recent developments with its European operations.
Jan 24, 2017
Volume is a key word for life sciences play Cellmid (ASX: CDY). Its key hair loss product Evolis® aims to replace thinning hair with voluminous locks, while management seeks to volumise revenues, stock liquidity, and ultimately shareholders’ returns.
Jan 18, 2017
It has been a busy two months for Creso Pharma (ASX: CPH) since we last featured the company in November 2016 and certainly a happy new year thus far with the news that CPH recently obtained the first ever EU registration for two CBD-based animal feed nutraceutical products.
Nov 10, 2016
If you hadn’t already heard, cannabis is currently undergoing a breath-taking liberation across the globe as doctors, clinics and government departments all gradually realise its medicinal and commercial endowments.
Nov 7, 2016
The medicinal cannabis industry, whilst attracting a lot of publicity, is still in its early stages as a new niche with very few current or even experienced market participants. Even the big pharma companies have so far been apprehensive towards taking significant stakes in medicinal cannabis, and have preferred to wait out the legislative rigmarole making headlines in the US, Europe and Australia.
Oct 26, 2016
Earlier this month, actor and director Ben Stiller publicised the fact he fought (and beat) an aggressive form of prostate cancer in 2014. He states his success over the oft-deadly disease is down to a PSA test that he took at an earlier age than what doctors commonly recommend.
Oct 20, 2016
The low-risk health profile of medical cannabis (MC) has finally gained enough traction to allow legislation to soften… which is why many investors have raised their binoculars on the lookout for bright medical cannabis companies at an early stage of development.
Oct 10, 2016
There could be a light at the end of the tunnel for chronic kidney disease sufferers, suffering from a rare form of the disease known as focal segmental glomerulosclerosis (FSGS). In fact several multi-million dollar companies in the space are dedicated to delivering life changing therapies to people living with chronic kidney disease with significant unmet medical needs.
Oct 6, 2016
As Australia prepares for the legalisation of medicinal marijuana in November – following bipartisan support at a Federal level and a formal decision by the Therapeutic Goods Administration – the future is looking encouraging for medical cannabis company MGC Pharmaceuticals (ASX:MXC).
Sep 14, 2016
Calendar year 2016 will go down as a dynamic period of growth in the life of Cellmid (ASX: CDY), a revenue generating life sciences company with lead programs in multiple disease indications and a consumer health business which has just come into its own in the last 12 months.